A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
For more information about the trial above please contact the study team:
Principal Investigator, Theodore Gourdin, at firstname.lastname@example.org.
Study Coordinator, Carly Fecio, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina